← Back to screener

Tango Therapeutics, Inc. TNGX

Rank #2355 · Nasdaq · $3.3B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
22.3
P/E
-32.3
P/B
13.17
ROE
-40.8%
Op. Margin
-312.6%
Debt Ratio
47%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -32.3x, P/B 13.17x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -40.8%. Ranks in the top 90% of the universe.

Safety ★★★★☆
Good

Debt ratio 47%. Ranks in the top 22% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 46.9% year over year. Ranks in the top 8% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–––$0.0B–119
2021$0.0B$-0.1B$-0.1B$0.0B-681.82133
2022$0.0B$-0.1B$-0.1B$0.0B-157.1403
2023$0.0B$-0.1B$-0.1B$0.3B-446.854
2024$0.0B$-0.1B$-0.1B$0.3B-446.843
2025$0.0B$-0.1B$-0.1B$0.2B-312.647

← See the full screener